Pharmacokinetics of Darunavir/Ritonavir With Etravirine Both Twice Daily in Human Immunodeficiency Virus-Infected Adolescents and Young Adults

J Pediatric Infect Dis Soc. 2017 Sep 1;6(3):294-296. doi: 10.1093/jpids/piw017.

Abstract

Data on the combination of darunavir/ritonavir and etravirine both given twice daily in adolescents/young adults are lacking. In this study, we assessed the pharmacokinetics of darunavir/ritonavir 600/100 mg with etravirine 200 mg twice daily in 36 treatment-experienced human immunodeficiency virus-infected adolescents and young adults and found that exposures were comparable to those reported in adults.

Keywords: antiretrovirals; darunavir; etravirine; pediatrics; ritonavir.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Observational Study

MeSH terms

  • Adolescent
  • Darunavir / administration & dosage
  • Darunavir / pharmacokinetics*
  • Darunavir / therapeutic use
  • Drug Administration Schedule
  • Drug Combinations
  • Female
  • HIV Infections / drug therapy*
  • HIV Protease Inhibitors / administration & dosage
  • HIV Protease Inhibitors / pharmacokinetics*
  • HIV Protease Inhibitors / therapeutic use
  • Humans
  • Male
  • Pyridazines / administration & dosage
  • Pyridazines / pharmacokinetics*
  • Pyridazines / therapeutic use
  • Reverse Transcriptase Inhibitors / administration & dosage
  • Reverse Transcriptase Inhibitors / pharmacokinetics*
  • Reverse Transcriptase Inhibitors / therapeutic use
  • Ritonavir / administration & dosage
  • Ritonavir / pharmacokinetics*
  • Ritonavir / therapeutic use
  • Viral Load / drug effects
  • Young Adult

Substances

  • Drug Combinations
  • HIV Protease Inhibitors
  • Pyridazines
  • Reverse Transcriptase Inhibitors
  • etravirine
  • Ritonavir
  • Darunavir